United States

People: Immunomedics Inc (IMMU.OQ)

IMMU.OQ on NASDAQ Stock Exchange Global Market

4:00pm EDT
Change (% chg)

$0.25 (+1.04%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Pehl, Michael 

Mr. Michael F. Pehl has been appointed President, Chief Executive Officer, Director of the Company., effective on December 7, 2017. Mr. Pehl most recently served as President, Hematology & Oncology, at Celgene Corporation ("Celgene"), and prior to that was Head of Global Marketing for the Company in both the United States and in Europe. Mr. Delaney was most recently at Celgene where he served as Vice President, U.S. Commercial Hematology Oncology.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --